Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma

scientific article published on 21 February 2019

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1172/JCI.INSIGHT.127684
P932PMC publication ID6478404
P698PubMed publication ID30830874

P50authorCarl H. JuneQ19277113
Marcela V. MausQ38321614
William MatsuiQ38326712
Dan T VoglQ42576934
Simon F LaceyQ56978267
Adam D CohenQ63987185
Alfred L GarfallQ80726281
Edward A. StadtmauerQ85544110
Megan M. DavisQ85544115
Irina KulikovskayaQ85544118
Anne LamontagneQ85544147
Donald L. SiegelQ85544150
Bruce L. LevineQ85544154
Regina M. YoungQ85544157
Michael C MiloneQ88137713
Emily C AyersQ89776169
Jan MelenhorstQ90374440
Martin CarrollQ92827331
Brendan M WeissQ95945848
Kavita DhodapkarQ98394175
Naseem D S KerrQ117283215
Karen DengelQ117283217
Maria KrevvataQ117283232
Selene Nunez-CruzQ117283233
P2093author name stringQiuju Wang
Rituparna Das
Patricia A Mangan
Wei-Ting Hwang
Madhav V Dhodapkar
P433issue4
P921main subjectstem cell transplantationQ65592366
P577publication date2019-02-21
P1433published inJCI insightQ27727187
P1476titleAnti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
P478volume4

Reverse relations

cites work (P2860)
Q90080719CAR T and CAR NK cells in multiple myeloma: Expanding the targets
Q98771206CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
Q91130368CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives
Q92052107Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
Q92095447Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD
Q97527436The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

Search more.